Supernus Announces Pricing of $350 Million Private Offering of 0.625% Convertible Senior Notes

Mar 15, 2018 ROCKVILLE, Md., March 15, 2018 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) (the “Company”), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced today the pricing of its private offering of $350